secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0001193125-24-172225
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 5.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics cuts workforce by 43%, two executives depart
--------------------------------------------------------------

- Workforce reduced by 17 employees (~43% of headcount); one-time severance charge of ~$4.0M; substantially complete by Q3 2024.
- General Counsel Thomas Perone and COO Jason Tardio depart effective July 11, 2024; consulting transition arrangements planned.
- Cash runway extended into first half of 2026 due to cost savings from workforce reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000119312524172225/0001193125-24-172225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000119312524172225/d822326d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-172225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer